Literature DB >> 23986396

Universal flu vaccines: primum non nocere.

James E Crowe1.   

Abstract

Envisioning universal influenza vaccines that induce antibodies to conserved viral epitopes is exciting, but first we need to better understand the balance of effects caused by neutralizing and nonneutralizing antibodies (Khurana et al., this issue).

Mesh：

Substances：

Year:  2013        PMID： 23986396     DOI： 10.1126/scitranslmed.3007118

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  12 in total

1.  Identification and characterization of the constituent human serum antibodies elicited by vaccination.

Authors:  Jason J Lavinder; Yariv Wine; Claudia Giesecke; Gregory C Ippolito; Andrew P Horton; Oana I Lungu; Kam Hon Hoi; Brandon J DeKosky; Ellen M Murrin; Megan M Wirth; Andrew D Ellington; Thomas Dörner; Edward M Marcotte; Daniel R Boutz; George Georgiou
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

2.  Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics.

Authors:  Katie L Winarski; Juanjie Tang; Laura Klenow; Jeehyun Lee; Elizabeth M Coyle; Jody Manischewitz; Hannah L Turner; Kazuyo Takeda; Andrew B Ward; Hana Golding; Surender Khurana
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-11       Impact factor: 11.205

Review 3.  Continuing challenges in influenza.

Authors:  Robert G Webster; Elena A Govorkova
Journal:  Ann N Y Acad Sci       Date:  2014-05-30       Impact factor: 5.691

Review 4.  Influenza Virus and SARS-CoV-2 Vaccines.

Authors:  Adam M Sandor; Michael S Sturdivant; Jenny P Y Ting
Journal:  J Immunol       Date:  2021-05-21       Impact factor: 5.426

Review 5.  B Cells and Functional Antibody Responses to Combat Influenza.

Authors:  Giuseppe Lofano; Arun Kumar; Oretta Finco; Giuseppe Del Giudice; Sylvie Bertholet
Journal:  Front Immunol       Date:  2015-06-30       Impact factor: 7.561

6.  Pan-Influenza A Protection by Prime-Boost Vaccination with Cold-Adapted Live-Attenuated Influenza Vaccine in a Mouse Model.

Authors:  Yo Han Jang; Joo Young Kim; Young Ho Byun; Ahyun Son; Jeong-Yoon Lee; Yoon Jae Lee; Jun Chang; Baik Lin Seong
Journal:  Front Immunol       Date:  2018-02-01       Impact factor: 7.561

Review 7.  Influenza and Antibody-Dependent Cellular Cytotoxicity.

Authors:  Tarra A Von Holle; M Anthony Moody
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

8.  Randomized controlled ferret study to assess the direct impact of 2008-09 trivalent inactivated influenza vaccine on A(H1N1)pdm09 disease risk.

Authors:  Danuta M Skowronski; Marie-Eve Hamelin; Gaston De Serres; Naveed Z Janjua; Guiyun Li; Suzana Sabaiduc; Xavier Bouhy; Christian Couture; Anders Leung; Darwyn Kobasa; Carissa Embury-Hyatt; Erwin de Bruin; Robert Balshaw; Sophie Lavigne; Martin Petric; Marion Koopmans; Guy Boivin
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

9.  A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques.

Authors:  Sujin Lee; Minh Trang Nguyen; Michael G Currier; Joe B Jenkins; Elizabeth A Strobert; Adriana E Kajon; Ranjna Madan-Lala; Yury A Bochkov; James E Gern; Krishnendu Roy; Xiaoyan Lu; Dean D Erdman; Paul Spearman; Martin L Moore
Journal:  Nat Commun       Date:  2016-09-22       Impact factor: 14.919

10.  AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization.

Authors:  Surender Khurana; Elizabeth M Coyle; Jody Manischewitz; Lisa R King; Jin Gao; Ronald N Germain; Pamela L Schwartzberg; John S Tsang; Hana Golding
Journal:  NPJ Vaccines       Date:  2018-10-01       Impact factor: 7.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.